Figure 8From: RadioImmunotherapy for adenoid cystic carcinoma: a single-institution series of combined treatment with cetuximaboverall progression-free survival (PFS); mean PFS: 22,1 mo, median PFS: 29,6 mo [95% CI: 11,9 - 29,6 mo]; PFS @ 2a: 62,5%.Back to article page